A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate.

IF 6.9 1区 医学 Q1 IMMUNOLOGY
Rory C F de Brito, Yashar Sadigh, Joseph Bowman, Stephanie Clive, Ben Jackson, Miriam Pedrera, Fraser Crofts, Matthieu Bernard, Fabian Z X Lean, Alejandro Núñez, Julian Seago, Jean-Pierre Frossard, Simon P Graham
{"title":"A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate.","authors":"Rory C F de Brito, Yashar Sadigh, Joseph Bowman, Stephanie Clive, Ben Jackson, Miriam Pedrera, Fraser Crofts, Matthieu Bernard, Fabian Z X Lean, Alejandro Núñez, Julian Seago, Jean-Pierre Frossard, Simon P Graham","doi":"10.1038/s41541-025-01192-z","DOIUrl":null,"url":null,"abstract":"<p><p>More efficacious vaccines are required to improve control of porcine reproductive and respiratory syndrome viruses (PRRSV). One strategy that has shown promise is the use of centralized antigens, generated from consensus sequence data. Here, we evaluated the consensus sequence approach to develop a PRRSV-1 modified live virus (MLV) vaccine candidate, 'EU-PRRSV-Con'. EU-PRRSV-Con strain was engineered by inserting consensus sequence open-reading frames encoding envelope proteins of 67 PRRSV-1 strains into an attenuated PRRSV-1 strain backbone. EU-PRRSV-Con was evaluated in pigs and benchmarked against a licensed MLV vaccine. Efficacy was assessed against three different PRRSV-1 isolates. Neutralizing antibodies were elicited by EU-PRRSV-Con, which were more reactive than those induced by the licensed MLV. EU-PRRSV-Con provided better levels of protection (reduced viral loads and lung pathology) than the licensed MLV, although the efficacy against a divergent PRRSV-1 subtype 3 strain was more limited. These data support the development of EU-PRRSV-Con as a vaccine that may aid control of PRRSV-1.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"129"},"PeriodicalIF":6.9000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-025-01192-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

More efficacious vaccines are required to improve control of porcine reproductive and respiratory syndrome viruses (PRRSV). One strategy that has shown promise is the use of centralized antigens, generated from consensus sequence data. Here, we evaluated the consensus sequence approach to develop a PRRSV-1 modified live virus (MLV) vaccine candidate, 'EU-PRRSV-Con'. EU-PRRSV-Con strain was engineered by inserting consensus sequence open-reading frames encoding envelope proteins of 67 PRRSV-1 strains into an attenuated PRRSV-1 strain backbone. EU-PRRSV-Con was evaluated in pigs and benchmarked against a licensed MLV vaccine. Efficacy was assessed against three different PRRSV-1 isolates. Neutralizing antibodies were elicited by EU-PRRSV-Con, which were more reactive than those induced by the licensed MLV. EU-PRRSV-Con provided better levels of protection (reduced viral loads and lung pathology) than the licensed MLV, although the efficacy against a divergent PRRSV-1 subtype 3 strain was more limited. These data support the development of EU-PRRSV-Con as a vaccine that may aid control of PRRSV-1.

采用集中免疫原方法开发具有更广泛保护作用的改良活猪繁殖与呼吸综合征病毒1型候选疫苗
需要更有效的疫苗来改善对猪繁殖与呼吸综合征病毒(PRRSV)的控制。一种显示出希望的策略是使用集中式抗原,由一致序列数据生成。在这里,我们评估了共识序列方法来开发PRRSV-1修饰活病毒(MLV)候选疫苗“EU-PRRSV-Con”。通过将编码67株PRRSV-1毒株包膜蛋白的一致序列开放阅读框架插入到减毒的PRRSV-1毒株主干中,构建EU-PRRSV-Con毒株。在猪身上对EU-PRRSV-Con进行了评估,并与一种获得许可的MLV疫苗进行了基准测试。对三种不同的PRRSV-1分离株进行了疗效评估。EU-PRRSV-Con诱导的中和抗体反应性比许可的MLV诱导的更强。EU-PRRSV-Con提供了比许可的MLV更好的保护水平(减少病毒载量和肺部病理),尽管对PRRSV-1亚型3菌株的疗效更为有限。这些数据支持开发EU-PRRSV-Con疫苗,这可能有助于控制PRRSV-1。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信